A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShanghai Pulmonary Hospital, Shanghai, China
About this trial
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
Eligibility criteria
Qualifiers
RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin).
Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.
Disqualifiers
Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.
Test confirms poor response to ZOL and IL-2 stimulation.
Trial design
Treatments tested in this trial
- Vγ2Vδ2 T lymphocyte-based immunotherapy
- Treatment regimens for MDR-TB
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Shanghai Pulmonary Hospital, Shanghai, China
Lead sponsor
Shanghai Public Health Clinical Center
Collaborator
Huashan Hospital
Collaborator
No.85 Hospital, Changning, Shanghai, China
Collaborator
Source ClinicalTrials.gov